☆ 4.8 Article

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

LANCET (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

News Item Medicine, General & Internal

Nature does things well

[Anonymous]

EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2022)

添加到收藏夹

Article Medicine, General & Internal

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Peter W. Horby et al.

Summary: In patients hospitalized with COVID-19, aspirin was not associated with reductions in 28-day mortality or in the risk of progressing to invasive mechanical ventilation or death, but was associated with a small increase in the rate of being discharged alive within 28 days.

LANCET (2022)

添加到收藏夹

Article Critical Care Medicine

Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial

E. Wesley Ely et al.

Summary: This study evaluated the efficacy and safety of baricitinib plus standard of care in critically ill COVID-19 patients. The results showed that compared to placebo, treatment with baricitinib significantly reduced mortality at both 28 and 60 days. Additionally, there were no significant differences in ventilator-free days and hospitalization duration between the baricitinib and placebo groups.

LANCET RESPIRATORY MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Dexamethasone in Hospitalized Patients with Covid-19

Peter Horby et al.

Summary: In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Genetic mechanisms of critical illness in COVID-19

Erola Pairo-Castineira et al.

Summary: In critically ill patients with COVID-19, host genetic variants associated with antiviral defense mechanisms and inflammatory organ damage were identified through a genome-wide association study. These genetic signals provide potential targets for therapeutic development and repurposing of existing drugs. Large-scale randomized clinical trials will be essential to confirm the effectiveness of targeted treatment strategies.

NATURE (2021)

添加到收藏夹

Article Medicine, General & Internal

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

A. C. Kalil et al.

Summary: Combination treatment with baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

P. W. Horby et al.

Summary: Azithromycin has been proposed as a treatment for COVID-19 due to its immunomodulatory actions. However, a study in hospitalized patients with COVID-19 showed that azithromycin did not improve survival or other clinical outcomes. Its use should be restricted to patients with a clear antimicrobial indication.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani et al.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Peter W. Horby et al.

Summary: Convalescent plasma therapy did not improve survival or other clinical outcomes in hospitalized COVID-19 patients.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 AMeta-analysis

Manu Shankar-Hari et al.

Summary: This study identified 27 clinical trials and found that the use of IL-6 antagonists was associated with lower 28-day all-cause mortality in patients hospitalized for COVID-19 compared to usual care or placebo. Different risk effects were observed between tocilizumab and sarilumab, increasing understanding of the treatment with these drugs.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

Patricia O. Guimaraes et al.

Summary: Among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo. The mortality rate was lower in the tofacitinib group within 28 days. However, the rate of serious adverse events was similar in both groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Critical Care Medicine

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER) : a randomised, double-blind, parallel-group, placebo- controlled phase 3 trial

Vincent C. Marconi et al.

Summary: Although there was no significant reduction in the frequency of disease progression overall, treatment with baricitinib in addition to standard of care (including dexamethasone) had a similar safety profile to that of standard care alone, and was associated with reduced mortality in hospitalised adults with COVID-19.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Critical Care Medicine

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Group Author Only

Summary: The study aimed to evaluate the efficacy and safety of colchicine in treating COVID-19 patients, but found that it did not reduce 28-day mortality, hospital stay duration, or risk of progressing to invasive mechanical ventilation or death.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Peter Richardson et al.

LANCET (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Mechanism of baricitinib supports artificial intelligence-predicted testing inCOVID-19 patients

Justin Stebbing et al.

EMBO MOLECULAR MEDICINE (2020)

添加到收藏夹

Article Allergy

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Yang Cao et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Peter W. Horby et al.

LANCET (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

An inflammatory cytokine signature predicts COVID-19 severity and survival

Diane Marie Del Valle et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Peter Horby et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials

Jonathan A. C. Sterne et al.

TRIALS (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects

Shubhasree Banerjee et al.

DRUGS (2017)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.